Trending News

Trump Administration Issues AI Action Plan and AI Executive Orders

Winning the Race: America’s AI Action Plan

Innovation Over Regulation – Trump Unveils America’s AI Action Plan

Caught in the Act: Practical and Legal Considerations When Executives’ Office Love Affair Exposed

Florida’s CHOICE Act Becomes Law, Enhancing Certain Non-Compete Agreements

Labor Secretary Lifts Abeyance on OFCCP Disability and Veteran Matters

In Case You Missed It: DOL Prohibited From Collecting Liquidated Damages in Wage & Hour Pre-Litigation Investigations

SEC’s New Concept Release on Foreign Private Issuer Standards

What Regulated Businesses Should Know About the Supreme Court’s Recent NEPA Decision

NEW ATDS BATTLEGROUND: Texas Passes HUGE NEW AMENDMENT to Its State Telemarketing Law Reviving The Risk of Autodialer Cases

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Posted On Saturday, March 01, 2025
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
Posted On Saturday, March 01, 2025
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Posted On Friday, February 28, 2025
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Posted On Friday, February 28, 2025
Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update
Posted On Friday, February 28, 2025
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
Posted On Friday, February 28, 2025
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
Posted On Friday, February 28, 2025
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
Posted On Friday, February 28, 2025
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
Posted On Friday, February 28, 2025
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
Posted On Friday, February 28, 2025
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
Posted On Friday, February 28, 2025
Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting
Posted On Friday, February 28, 2025
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
Posted On Friday, February 28, 2025
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Posted On Friday, February 28, 2025
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
Posted On Friday, February 28, 2025
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Posted On Friday, February 28, 2025
BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
Posted On Friday, February 28, 2025
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
Posted On Friday, February 28, 2025
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
Posted On Friday, February 28, 2025
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Posted On Friday, February 28, 2025
Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration
Posted On Friday, February 28, 2025
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance
Posted On Friday, February 28, 2025
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Posted On Friday, February 28, 2025
Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan
Posted On Friday, February 28, 2025
Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris
Posted On Thursday, February 27, 2025

Print